Vaccine for cervical cancer virus promising

	Tweet

An experimental vaccine designed to protect against the virus responsible for Cervical cancer performed well in a late-stage trial, drugmaker Merck & Co., said on Thursday.

The vaccines aim to protect against strains of the sexually transmitted Human papilloma virus (HPV), a cause of cervical cancer, the second-biggest killer of women worldwide.

Merck said a trial of 1,529 people found that younger adolescent males and females receiving the treatment called Gardasil experienced a higher immune response compared with young women.

The company said it was the first trial to look at young people ages 10 to 15 years old.

Merck is racing rival GlaxoSmithKline Plc, which is working on its own product called Cervarix, and analysts believe the drugmakers are headed for a fierce marketing battle. 

RELATED STORIES:
Strong Drugs without the Addiction   Study supports controversial blood-thinning drug   Vioxx or Celebrex   Doctors question safety of U.S. drugs   Merck tried to bury Vioxx concerns for years   Putting an old drug to a new use   Cipla HIV drugs back on WHO approved list   Lamictal cuts effectiveness of the pill   UK doctors highlight over-the-counter drug risks   FDA says AstraZeneca Crestor ad is misleading   China’s new bird flu vaccine ready to go   Vertex says drug quickly treats hepatitis C

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]